We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+5.28%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$17.8B
AUM Growth
+$1.26B
(+7.6%)
Cap. Flow
+$567M
Cap. Flow
% of AUM
3.2%
Top 10 Holdings %
Top 10 Hldgs %
11.28%
Holding
2,904
New
221
Increased
694
Reduced
820
Closed
148
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$82.7M |
| 2 |
PepsiCo
PEP
|
+$76.8M |
| 3 |
Marriott International
MAR
|
+$64.8M |
| 4 |
Tyson Foods
TSN
|
+$62.8M |
| 5 |
PARA
Paramount Global Class B
PARA
|
+$52.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Starbucks
SBUX
|
+$64.8M |
| 2 |
Hormel Foods
HRL
|
+$61.4M |
| 3 |
Gilead Sciences
GILD
|
+$59.9M |
| 4 |
Hilton Worldwide
HLT
|
+$54.7M |
| 5 |
TechnipFMC
FTI
|
+$51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.87% |
| 2 | Healthcare | 14.18% |
| 3 | Financials | 11.71% |
| 4 | Industrials | 10.79% |
| 5 | Consumer Discretionary | 10.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
USCR
251
DELISTED
U S Concrete, Inc.
USCR
| $23.9M | 0.13% |
519,513
+3,854
| +0.7% | +$217K |
|
252
Viatris
VTRS
$20.1B
| $23.7M | 0.13% |
621,036
+105,498
| +20% | +$4.69M |
|
253
Dominion Energy
D
$62.5B
| $23.6M | 0.13% |
318,227
-7,892
| -2% | -$601K |
|
254
Cognizant
CTSH
$21.5B
| $23.3M | 0.13% |
489,091
-29,961
| -6% | -$1.7M |
|
255
Newell Brands
NWL
$2.16B
| $23.1M | 0.13% |
438,207
-201,466
| -31% | -$10.4M |
|
256
Akamai
AKAM
$16.8B
| $22.9M | 0.13% |
433,057
-42,654
| -9% | -$2.28M |
|
257
Kimberly-Clark
KMB
$36.4B
| $22.8M | 0.13% |
180,696
+121,478
| +205% | +$15.7M |
|
258
Iridium Communications
IRDM
$4.85B
| $22M | 0.12% |
2,710,720
-377,279
| -12% | -$3.16M |
|
259
Lockheed Martin
LMT
$134B
| $21.7M | 0.12% |
90,706
+232
| +0.3% | +$58.1K |
|
260
Progressive
PGR
$124B
| $21.7M | 0.12% |
687,604
-377,345
| -35% | -$12.3M |
|
261
Parker-Hannifin
PH
$125B
| $21.5M | 0.12% |
171,397
+2,515
| +1% | +$300K |
|
262
MillerKnoll
MLKN
$1.5B
| $21.5M | 0.12% |
752,177
-361,534
| -32% | -$11.9M |
|
263
iShares Select Dividend ETF
DVY
$24B
| $21.5M | 0.12% |
250,516
-1,353
| -0.5% | -$117K |
|
264
Vanguard FTSE Developed Markets ETF
VEA
$226B
| $21.5M | 0.12% |
573,713
-25,264
| -4% | -$929K |
|
265
Kinder Morgan
KMI
$73.1B
| $21.4M | 0.12% |
926,415
+436,691
| +89% | +$9.25M |
|
|
NPTN
266
DELISTED
NEOPHOTONICS CORP
NPTN
| $21.2M | 0.12% |
1,296,012
-199,358
| -13% | -$2.81M |
|
267
iShares Core S&P Small-Cap ETF
IJR
$109B
| $21.1M | 0.12% |
340,468
+14,614
| +4% | +$893K |
|
268
Church & Dwight Co
CHD
$23.1B
| $20.6M | 0.12% |
430,465
+386,235
| +873% | +$19.1M |
|
269
Smith & Nephew
SNN
$12.9B
| $20.5M | 0.12% |
624,458
+258,147
| +70% | +$8.66M |
|
|
AMTD
270
DELISTED
TD Ameritrade Holding Corp
AMTD
| $20.2M | 0.11% |
572,129
+118,378
| +26% | +$3.69M |
|
|
ALE
271
DELISTED
Allete
ALE
| $20.2M | 0.11% |
338,064
-400,202
| -54% | -$24.7M |
|
272
MSC Industrial Direct
MSM
$7.02B
| $19.9M | 0.11% |
270,563
+260,223
| +2,517% | +$18.9M |
|
273
Cincinnati Financial
CINF
$28.3B
| $19.8M | 0.11% |
262,199
-110,197
| -30% | -$8.34M |
|
274
Mettler-Toledo International
MTD
$26.8B
| $19.6M | 0.11% |
46,721
-66,896
| -59% | -$26.6M |
|
275
Bristol-Myers Squibb
BMY
$127B
| $19.5M | 0.11% |
361,427
-8,115
| -2% | -$521K |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q3 2016 Portfolio in Review
As of Q3 2016, Glenmede Trust held 2,904 positions worth $17.8B, up 7.6% from $16.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Glenmede Trust deployed $567M of net new capital in Q3 2016, opening 221 new positions and adding to 694 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 2,050,199 shares worth $37.2M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Starbucks, an estimated $64.8M trimmed.
- Glenmede Trust's largest Q3 2016 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 2,050,199 shares worth $37.2M.
- Glenmede Trust added most to McKesson in Q3 2016, an estimated $82.7M increase.
- Glenmede Trust's biggest Q3 2016 reduction was Starbucks, cutting an estimated $64.8M.
- Glenmede Trust fully exited WILSHIRE BANCORP INC in Q3 2016, selling an estimated $18.5M.
- Glenmede Trust's ten largest holdings make up 11% of its $17.8B portfolio in Q3 2016.
- Glenmede Trust opened 221 new positions and closed 148 in Q3 2016.
- Glenmede Trust's portfolio value rose 7.6% quarter-over-quarter to $17.8B.
Based on Glenmede Trust's 13F filing for Q3 2016, filed 14 Nov 2016.